Table 5.
Spearman’s Rho and Mann-Whitney test for comparison of clinicopathological parameters according to peripheral CD4+ and CD4+/CD8+ in TNBC.
| Clinicopathological characteristic | CD4+ | P value | CD4+/CD8+ Ratio | P value |
|---|---|---|---|---|
| Age(y) | 0.014 | 0.01 | ||
| ≤50 | 560.45 ± 393.92 | 1.49 ± 0.75 | ||
| >50 | 645.72 ± 324.37 | 1.68 ± 0.75 | ||
| Ki67 | 0.662 | 0.48 | ||
| Positive(≥14%) | 575.84 ± 363.19 | 1.57 ± 0.78 | ||
| Negative(<14%) | 680.76 ± 406.85 | 1.65 ± 0.68 | ||
| Pathologic T stage(Tumor size) | 0.17 | 0.539 | ||
| 1 | 679.89 ± 425.31 | 1.67 ± 0.81 | ||
| 2-4 | 556.96 ± 316.83 | 1.52 ± 0.72 | ||
| Pathologic N stage | 0.392 | 0.294 | ||
| 0 | 650.74 ± 434.27 | 1.55 ± 0.71 | ||
| 1-2 | 571.00 ± 291.57 | 1.63 ± 0.79 | ||
| 3 | 530.34 ± 257.78 | 1.43 ± 0.75 | ||
| Clinical stages | 0.001 | 0.237 | ||
| 0-1 | 725.91 ± 507.29 | 1.62 ± 0.75 | ||
| 2 | 677.97 ± 366.20 | 1.67 ± 0.93 | ||
| 3 | 698.36 ± 355.13 | 1.83 ± 0.83 | ||
| 4 | 522.24 ± 264.38 | 1.50 ± 0.71 | ||
| Bone invasion | 0.735 | 0.735 | ||
| Yes | 527.81 ± 126.51 | 1.66 ± 0.68 | ||
| No | 603.34 ± 368.81 | 1.57 ± 0.76 | ||
| Visceral invasion | 0.097 | 0.702 | ||
| Yes | 546.62 ± 297.20 | 1.55 ± 0.76 | ||
| No | 627.31 ± 389.96 | 1.59 ± 0.75 | ||
| Multiple invasion | 0.316 | 0.802 | ||
| Yes | 551.70 ± 304.16 | 1.53 ± 0.73 | ||
| No | 627.68 ± 390.48 | 1.60 ± 0.76 | ||
| Neoadjuvant therapy | 0.057 | 0.027 | ||
| Yes | 486.95 ± 268.77 | 1.34 ± 0.62 | ||
| No | 624.68 ± 376.63 | 1.63 ± 0.77 | ||
| Type of neoadjuvant treatment | 0.445 | 0.18 | ||
| Chemotherapy only | 486.68 ± 271.67 | 1.33 ± 0.62 | ||
| Chemotherapy combined with targeted therapy | – | – | ||
| Chemotherapy combined with immunotherapy | – | – | ||
| Postoperative adjuvant therapy | 0.246 | 0.619 | ||
| Yes | 602.72 ± 359.40 | 1.59 ± 0.77 | ||
| No | 590.93 ± 390.45 | 1.53 ± 0.69 | ||
| Type of adjuvant treatment | 0.3 | 0.325 | ||
| Chemotherapy only | 607.20 ± 359.70 | 1.59 ± 0.77 | ||
| Chemotherapy combined with targeted therapy | 179.36 | 1.58 | ||
| Chemotherapy combined with immunotherapy | – | – | ||
| Advanced treatment lines | <0.001 | 0.127 | ||
| 1 | 564.65 ± 301.96 | 1.54 ± 0.73 | ||
| 2 | 571.29 ± 295.23 | 1.62 ± 0.74 | ||
| ≥3 | 425.48 ± 234.31 | 1.46 ± 0.79 | ||
| Type of advanced treatment | 0.601 | 0.756 | ||
| Chemotherapy only | 546.07 ± 267.16 | 1.53 ± 0.74 | ||
| Chemotherapy combined with targeted therapy | 642.69 ± 420.000 | 1.50 ± 0.76 | ||
| Chemotherapy combined with Immunotherapy | 577.42 ± 436.67 | 1.71 ± 0.79 | ||
| BRCA status | 0.48 | 0.643 | ||
| Mutation | 387.62 ± 362.29 | 0.87 ± 0.52 | ||
| Non-mutation | 238.44 ± 259.65 | 1.04 ± 0.18 | ||
| Unknown | 608.06 ± 362.68 | 1.59 ± 0.75 | ||
| Family tumor history | 0.632 | 0.632 | ||
| Yes | 678.05 ± 570.60 | 1.56 ± 0.78 | ||
| No | 585.20 ± 304.46 | 1.58 ± 0.75 | ||
| Menstrual status | 0.551 | 0.055 | ||
| Premenopause | 634.84 ± 477.04 | 1.54 ± 0.80 | ||
| Postmenopause | 613.31 ± 323.27 | 1.59 ± 0.71 | ||
| KPS | 0.365 | 0.146 | ||
| ≥80 | 609.31 ± 377.60 | 1.59 ± 0.75 | ||
| 50-70 | 235.76 ± 201.17 | 1.29 ± 0.82 |
KPS, Karnofsky Performance Status.
Visceral metastasis includes the brain, liver, and lung metastasis. Multiple lesions occurred in the same organ only count once. The median value of lymphocytes was used as the cut-off value.
All P values were two-tailed-sided, and statistical significance was set as P < 0.05.